Cannabis Law Report

NOVEMBER 19, 2021

MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. We are committed to continuing to lead the field of psychedelic medicine with integrity and ethics at the core. Why work for MAPS Public Benefit Corporation (MAPS PBC)?

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

AUGUST 19, 2019

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

Medicine 45

Medicine Patients Clinical Trials Access 45

NewsMunchies

NOVEMBER 12, 2021

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. In Western medicine, the psychedelic revolution is coming at the perfect moment as the country grapples with a post-COVID world.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

JANUARY 26, 2022

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. Remember, the pharmaceutical model is “this medicine addresses this specific target.”

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. The millions of people afflicted with PTSD may soon have access to MDMA therapy, and we believe the millions suffering from TBI may experience similar relief in the future.”.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. We are committed to continuing to lead the field of psychedelic medicine with integrity and ethics at the core.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. 124’—the use and application of medicines manufactured from “marijuana” to any person are currently prohibited.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

NOVEMBER 19, 2021

MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. We are committed to continuing to lead the field of psychedelic medicine with integrity and ethics at the core. Why work for MAPS Public Benefit Corporation (MAPS PBC)?

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

CannaTech

SEPTEMBER 16, 2018

While Canada’s medicinal cannabis framework has gone through many iterations, Canada has led the way in showing to the world how to think about cannabis. What began as a legal medicine more than 15 years is now being legalized for adult recreational use. The Need for Cannabis Education Tailored to Patient and Doctor.

Education 66

Education Medicine Clinical Trials Patients 66

Veriheal

AUGUST 31, 2020

At Veriheal, education and diversity are at the center of our core values. Choosing only 10 winners for the $10,000 in scholarships among the strong applications we received from multiple disciplines and concentrations in higher education—from students of all backgrounds and interests—was extremely difficult. Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. n) any related matters.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. A doctor who applies to the TGA on behalf of a patient must provide a clinical justification.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

AUGUST 21, 2019

The National Institute for Health and Care Excellence (NICE) reviewed evidence for the benefits and costs of cannabis-based medicinal products and drew up guidance for health professionals and the public. It also said the children’s experiences on medicinal cannabis in the should be taken into account as evidence of how well the drug works.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

SpeedWeed

JULY 6, 2021

By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”. The US market for medicinal psychedelics is predicted to grow to $6.85 The US market for medicinal psychedelics is predicted to grow to $6.85 View original article.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. published the first edition of the MAPS Bulletin , titled “ MDMA Can Become a Legal Medicine ,” and the FDA rejected the second MDMA study protocol submitted by MAPS. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 19, 2021

MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. We are committed to continuing to lead the field of psychedelic medicine with integrity and ethics at the core. Why work for MAPS Public Benefit Corporation (MAPS PBC)?

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Peninsula Alternative Health

MAY 15, 2019

The challenging part is that every individual strain is a different medicine and every individual cancer is a different disease. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. Naturally, cells in our bodies are not mobile but cancer cells are.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MMJ Recs

DECEMBER 22, 2023

As more physicians and healthcare professionals advocate for the integration of medical marijuana into treatment plans, public trust in its medicinal value has grown. This shift can be attributed to increased access to information, a more liberal societal outlook, and a willingness to explore alternative healthcare options.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

JANUARY 9, 2019

Tindall was helping turnaround a business using his decades of experience in financial services, and also coming to terms with the death of his own father, when he had an awakening as to what medicinal cannabis was capable of. “I Tindall also hope to commence the clinical trials with Vanuatu for diabetes treatment.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

MMJ Recs

JUNE 15, 2022

Unique Pain Medicine. With three offices in NYC, Brooklyn, and Long Island, Unique Pain Medicine is conveniently located and takes multiple insurance plans. Located in Midtown, this clinic provides patients with easy access to their doctors – you can text, live chat, or book online for same-day appointments.

Patients 52

Patients Treatment Clinical Trials Therapy 52

Cannabis Law Report

OCTOBER 5, 2021

The Panel’s report will be considered by the Advisory Committee of Medicines Scheduling (ACMS) at the 3 November 2021 meeting. The review excludes pre-clinical trials (i.e. He obtained fellowship of the relevant Colleges in the UK, Australasia and Canada, as well as of the Australasian Chapter of Addiction Medicine.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

AUGUST 7, 2022

The CSA divides drugs into schedules according to their assessed risk, categorizing the most dangerous, addictive, and harmful substances that are deemed to not have any recognized medicinal use as “Schedule I.” Even with BTD, the path to FDA approval of a psychedelic medicine is still arduous and expensive. Where Laws Are Changing.

Law 74

Law Research and Development Therapy Treatment 74

Cannabis Law Report

DECEMBER 7, 2021

Our audacious mission is to create the new standard of trust and transparency consumers deserve and healthcare providers demand on these widely accessible potential therapies. The large scale and intentional heterogeneity of our studies can transform these consumer health products into democratized precision solutions.”.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JANUARY 14, 2020

CLICK IMAGE TO ACCESS COMMITTEE INFO PAGE. 171 , the “Legitimate Use of Medicinal Marihuana Act” or the “LUMMA” H.R. 171, Legitimate Use of Medicinal Marijuana Act. Legislation. 601 , the “Medical Cannabis Research Act of 2019” H.R. 2843, Marijuana Freedom and Opportunity Act.

Clinical Trials 69

Clinical Trials Programs Access DEA 69

Cannabis Law Report

AUGUST 2, 2021

SAN DIEGO–(BUSINESS WIRE)– Radicle Science , a transformative healthtech B-corp validating natural products for the first time, announces the launch of the Radicle ACES (Advancing CBD Education and Science) study. Eric Schudiske, eric@s2spr.com.

CBD 105

CBD Data Sleep Clinical Trials 105

Healer

MARCH 26, 2021

Dustin Sulak, an osteopath in Falmouth who has treated Gresh, is the founder of Integr8 Health and the medical cannabis education site healer.com. Opioids are a good medicine. The researchers stressed the need for large, well-designed clinical trials. This is why medicine is hard. WHAT ABOUT CBD?

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Veriheal

JUNE 7, 2021

Note: Veriheal does not support illegally consuming therapeutic substances like MDMA but acknowledges that it transpires because of the current illicit status of both, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Therapy 82

Therapy Treatment Conditions Clinical Trials 82

Cannabis Law Report

DECEMBER 2, 2021

Under the approved recommendations, students applying for psilocybin training programs are required to provide a description of their educational background and a written statement explaining their commitment and interest in becoming a psilocybin facilitator. Training Administration Recommendations. Training Curriculum Recommendations.

Law 52

Law Programs Therapy Education 52

Peninsula Alternative Health

MAY 15, 2019

The challenging part is that every individual strain is a different medicine and every individual cancer is a different disease. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response. Naturally, cells in our bodies are not mobile but cancer cells are.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access.

Research and Development 52

Research and Development Medicine Access Media 52